NEWS RELEASE

Nevro to Report Fourth Quarter and Full Year 2019 Financial Results

2/3/2020

Company to Host Conference Call on Tuesday, February 25, 2020 at 1:30 p.m. PT / 4:30 p.m. ET

REDWOOD CITY, Calif., Feb. 3, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the Company will release its financial results for the fourth quarter and full year ended December 31, 2019 after the market closes on February 25, 2020.

Investors interested in listening to the conference call may do so by dialing (833) 286-5807 in the U.S. or (647) 689-4452 internationally, using Conference ID: 1864387. In addition, a live webcast, as well as an archived recording, will be available on the "Investors" section of the Company's website at: **www.nevro.com**.

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. HF10 therapy has demonstrated the ability to reduce or eliminate opioids in ≥65% of patients across six peer-reviewed clinical studies. The Senza® System, Senza II™ System, and the Senza® Omnia™ System are the only SCS systems that deliver Nevro's proprietary HF10® therapy. Senza, Senza II, Senza Omnia, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.

To learn more about Nevro, connect with us on **LinkedIn**, **Twitter**, **Facebook** and **Instagram**.

Investor Relations:

Juliet Cunningham
Vice President, Investor Relations

650-433-3247

ir@nevro.com

View original content to download multimedia:**http://www.prnewswire.com/news-releases/nevro-to-report-fourth-quarter-and-full-year-2019-financial-results-300997341.html**

SOURCE Nevro Corp.